June 2026 in “Pharmaceuticals” This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.
May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
January 2026 in “Frontiers in Pharmacology” This pharmacovigilance study identified 19 drugs with high potential risk for causing male infertility, including hormonal agents, antineoplastic drugs, and antidepressants, emphasizing the need for fertility counseling and possible sperm cryopreservation in reproductive-age males before using such treatments.
February 2024 in “Urology” This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.
June 2026 in “EP Europace” This study found that minoxidil and finasteride, commonly used for androgenetic alopecia, were associated with different arrhythmia profiles in adverse event reports: minoxidil predominantly with supraventricular arrhythmias and finasteride primarily with ventricular arrhythmias in men.